Media stories about Zimmer Biomet (NYSE:ZBH) have been trending somewhat positive on Tuesday, Accern reports. The research firm identifies positive and negative news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Zimmer Biomet earned a coverage optimism score of 0.10 on Accern’s scale. Accern also assigned news stories about the medical equipment provider an impact score of 46.3088836775366 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Here are some of the media headlines that may have effected Accern Sentiment’s rankings:
Shares of Zimmer Biomet (ZBH) traded up $0.67 on Tuesday, hitting $115.49. The company’s stock had a trading volume of 1,261,078 shares, compared to its average volume of 1,358,476. Zimmer Biomet has a one year low of $100.69 and a one year high of $133.49. The firm has a market cap of $23,460.00, a price-to-earnings ratio of 14.20, a price-to-earnings-growth ratio of 1.78 and a beta of 1.15. The company has a debt-to-equity ratio of 0.88, a quick ratio of 0.78 and a current ratio of 1.47.
Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Wednesday, November 1st. The medical equipment provider reported $1.72 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.74 by ($0.02). The business had revenue of $1.82 billion during the quarter, compared to analyst estimates of $1.83 billion. Zimmer Biomet had a net margin of 8.36% and a return on equity of 16.29%. The business’s revenue for the quarter was down .8% on a year-over-year basis. During the same period in the previous year, the company earned $1.79 earnings per share. analysts anticipate that Zimmer Biomet will post 8.03 earnings per share for the current year.
A number of research firms have weighed in on ZBH. Jefferies Group restated a “buy” rating and issued a $136.00 price target on shares of Zimmer Biomet in a report on Friday, November 3rd. Stifel Nicolaus restated a “hold” rating and issued a $120.00 price target on shares of Zimmer Biomet in a report on Friday, November 3rd. Gabelli began coverage on Zimmer Biomet in a report on Thursday, August 24th. They issued a “buy” rating and a $142.00 price target for the company. SunTrust Banks restated a “buy” rating and issued a $136.00 price target on shares of Zimmer Biomet in a report on Monday, October 2nd. Finally, Zacks Investment Research cut Zimmer Biomet from a “hold” rating to a “strong sell” rating in a report on Tuesday, August 8th. Four analysts have rated the stock with a sell rating, seven have issued a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $133.71.
TRADEMARK VIOLATION NOTICE: “Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Zimmer Biomet (ZBH) Share Price” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another publication, it was illegally stolen and republished in violation of US & international trademark & copyright law. The legal version of this article can be read at https://www.dispatchtribunal.com/2017/12/05/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-zimmer-biomet-zbh-share-price.html.
Zimmer Biomet Company Profile
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.